AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
12.4 C
New York
Tuesday, October 20, 2026

Tag: cell

KFSH Demonstrates How Specialized Hospitals Can Drive Health System Innovation at HLTH Europe 2026

AMSTERDAM, June 15, 2026 (GLOBE NEWSWIRE) -- Through its sponsorship and participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, King Faisal Specialist Hospital & Research Centre (KFSH) is demonstrating how specialized hospitals can become engines of health-system innovation by turning advanced science, digital infrastructure, and operational redesign into measurable improvements in care.

Stem Cell Therapy Market worth $3.65 billion by 2035 | MarketsandMarkets™

DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Stem Cell Therapy Market is projected to grow from about USD 0.48 billion...

Process Industries Converge in Houston for Inaugural ChemE Show 2026 Powered by ACHEMA

Two days of main stage programming, technical sessions, and hands-on technology evaluation drew engineers, plant managers, and decision-makers from across the chemicals, pharmaceutical, and...

IntelliGenome Announces Strategic Partnership with CTR Scientific to Advance CRISPR-TB in Mexico

HOUSTON and MONTERREY, Mexico, June 15, 2026 /PRNewswire/ -- IntelliGenome, Inc. today announced a strategic partnership with CTR Scientific (Control Técnico y Representaciones S.A....

Tethis announces application note of SmartBioSurface® slides for cell suspension workflows on leading spatial biology platform

MILAN, June 15, 2026 /PRNewswire/ -- Addressing a critical technical limitation in multi-cycle imaging - the reliable adhesion and retention of suspension-derived, non-adherent cells...

Tethis announces application note of SmartBioSurface® slides for cell suspension workflows on leading spatial biology platform

MILAN, June 15, 2026 /PRNewswire/ -- Addressing a critical technical limitation in multi-cycle imaging - the reliable adhesion and retention of suspension-derived, non-adherent cells...

Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity

Enterome presented new interim data from the ongoing Phase 1/2 SIDNEY study of OncoMimics™ EO2463 in patients with indolent non-Hodgkin lymphoma.

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026

SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster...

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery...

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell